How long is topical Fin “active” on the scalp? Finasteride/Dutasteride 12/13/2023
Topical finasteride remains active on the scalp for a certain period after application, and there is concern about the safety of touching the hair and transferring the medication to the fingers.
View this post in the Community →
Similar Community Posts Join
6 / 6 resultscommunity 3 months on topical min + fin + Redensyl and hair is worse. Nonstop shedding & dry flaky scalp
A 25-year-old male is experiencing worsening hair loss after 3 months of using topical minoxidil, finasteride, and Redensyl, with users suggesting patience, potential hormonal factors, and considering alternative treatments like dutasteride and oral minoxidil. Shedding is noted as a common phase, indicating potential future hair regrowth.
community (Topical) Finasteride cleared my scalp from miniaturised hair (female).
A female user's experience with topical and oral finasteride for hair loss, which has been successful as evidenced by the reduction of miniaturized hairs. Replies to the post discussed the recommended dosage for females versus males.
community Topical FIN/MIN 0.03% / 6% (Day 2) HAIR IS CURRENTLY WET & PARTED. As you can see my main issues are the crown / mid scalp area. Can’t wait until I start seeing results!
The conversation discusses using topical finasteride and minoxidil for hair loss, focusing on the crown and mid-scalp areas. The user is optimistic about seeing results in 3 to 6 months.
community Combining oral dut with topical finasteride for reduced scalp DHT
The conversation discusses combining oral dutasteride with topical finasteride to further reduce scalp DHT levels for hair regrowth. Users debate the effectiveness and safety of this combination, with some suggesting alternatives like topical antiandrogens such as RU58841, fluridil, and alfatradiol.
community How to apply topical Fin with this cone? Feel like everything is stuck on my hair and does not reach my scalp. Feels less effective than oral fin.
The conversation discusses switching from oral to topical finasteride for hair loss, with concerns about application methods and side effects like dizziness and low energy. Users suggest mixing finasteride with minoxidil for better scalp coverage and dosage control.
community Hairline still receding after nearly 8 months on finasteride — wait or consider dutasteride?
The user has been on oral finasteride for nearly eight months without significant improvement in hair loss and is considering switching to dutasteride. Suggestions include continuing finasteride, adding minoxidil, or trying alternative treatments like topical solutions or scalp massages.
Related Research
6 / 6 results
research Medical Management Options for Hair Loss
This review discusses both conventional and new pharmaceutical treatments for hair loss, as well as various natural and herbal remedies, but reports no new clinical results.
research Hair Loss in Women
This review discusses the classifications, diagnostic methods, and treatment strategies for female pattern hair loss, but reports no clinical results.
research Pattern Hair Loss in Men
This article reviews current knowledge on the causes, diagnosis, and medical treatments for androgenetic alopecia, particularly in men, and reports no new findings.
research Alopecia androgenética: aspectos etiopatogênicos, métodos diagnósticos e condutas terapêuticas
This review discusses the characteristics, causes, diagnosis, and treatment options for androgenetic alopecia and emphasizes the importance of managing expectations due to the variability in therapeutic outcomes.
research B‐ RAF , naevi and melanoma: a complex relationship
Male hair loss is mainly due to thinner hair, not less hair.
research Expert consensus for prevention, diagnosis and management of persistent chemotherapy-induced alopecia.
In this Delphi study, international experts established consensus-based guidelines for diagnosing and managing persistent chemotherapy-induced alopecia (pCIA), recommending prevention through scalp cooling and early use of minoxidil, while advising against bicalutamide and certain finasterides for breast cancer patients due to safety concerns.